EN DE
STOCK COMPARISON

NextCell Pharma AB vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how NextCell Pharma AB (NXTCL) and Vertex Pharmaceuticals (VRTX) compare, as of Sep 25, 2026.

As of Sep 25, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the more attractively valued of the two: NextCell Pharma AB trades at SEK 1.01 versus a fair value of SEK 0.34 (-66%), while Vertex Pharmaceuticals trades at $522 versus $575 (+10%).
NextCell Pharma AB
NXTCL.ST · SEK · Health Care
-66%
upside to fair value
overvalued
PriceSEK 1.01
Fair ValueSEK 0.34
Quality37/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
+10%
upside to fair value
undervalued
Price$522
Fair Value$575
Quality80/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green is the better side of a row, red the weaker one (for valuation multiples: lower = cheaper). Grey rows are for reference only and are not scored.

betterweakerfor reference, not scored

NextCell Pharma ABVertex Pharmaceuticals
Valuation
n/aP/E (TTM)30.7×
n/aP/E ex one-offs (FY2025)31.0×
1.24×P/S (TTM)10.90×
0.17×P/B7.14×
n/aEV/EBITDA25.8×
n/aPEG1.72×
−66.4%Fair value upside+10.0%
Profitability
n/aOperating margin38%
n/aEBIT margin trend (5Y)0.86×
-52%Return on equity24%
-28%Return on assets12%
Growth
-18%Revenue growth (YoY)8%
25.1%Avg. growth/yr (3Y)10.6%
25.1%Avg. growth/yr (5Y)14.2%
n/aValue creation/yr+13.5%
Balance & size
n/aInterest coverage (EBIT/interest)357.9×
n/aDebt / equity0.03×
$11MMarket cap$133B
expensiveGrowth qualityhealthy
The P/E excluding one-off items is only shown where the special items are documented in the accounts (our own raw data or SEC filings). If one side lacks it, the reported P/E stays scored.

NextCell Pharma AB leads: 4 to 3 metric wins.

n/a = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

NextCell Pharma ABof which business quality 37 · market factors 36 Vertex Pharmaceuticalsof which business quality 78 · market factors 75
ProfitabilityMargins and returns on capital today
0
72
Quality GrowthAre margins and returns improving?
56
65
CashflowEarnings quality: real cash, not paper profit
14
79
Fin. StrengthBalance sheet, leverage, solvency risk
93
92
InvestmentDisciplined investing over empire-building
67
58
Low VolatilityCalm price path (market factor)
41
85
MomentumPrice trend over the last 3–12 months (market factor)
34
66
52W MomentumDistance to the 52-week high (market factor)
34
78
Net IssuanceShare count: buybacks or dilution?
0
89

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyNextCell Pharma ABPrice SEK 1.01Vertex PharmaceuticalsPrice $522
DCF Modelsn/a-13%close to the price$454
Earnings-Basedn/a-1%close to the price$517
Multiplesn/a-47%below the price$279
Asset-Based-60%below the priceSEK 0.40-91%below the price$49.34
Growth DCFn/a-33%below the price$349
Economic Profitn/a-53%below the price$245
Growth Earningsn/a+33%above the price$693
Minimum-60%below the priceSEK 0.40-91%below the price$49.34
Maximum-60%below the priceSEK 0.40+33%above the price$693
Median-60%below the priceSEK 0.40-33%below the price$349
Geometric mean-60%below the priceSEK 0.40-44%below the price$294

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

NextCell Pharma AB: 1 of 1 models see the stock below the current price.

Vertex Pharmaceuticals: 19 of 24 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

NextCell Pharma AB
Price SEK 1.01
Fair Value SEK 0.34
Bear SEK 0.22Bull SEK 0.42
Vertex Pharmaceuticals
Price $522
Fair Value $575
Bear $345Bull $1,244

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

NextCell Pharma AB · Health Care

Quality score37 · bottom 25%
Fair value upside-66% · bottom 25%

Vertex Pharmaceuticals · Health Care

Quality score80 · Top 25%
Fair value upside+10% · above median

Bottom line

As of Sep 25, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the more attractively valued of the two: NextCell Pharma AB trades at SEK 1.01 versus a fair value of SEK 0.34 (-66%), while Vertex Pharmaceuticals trades at $522 versus $575 (+10%).

Vertex Pharmaceuticals has the higher quality score (80/100).

Open Vertex Pharmaceuticals live analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.